BAIBYS team. – company pic
BAIBYS is an Israeli startup that has developed an AI-powered system that autonomously selects optimal sperm for fertility treatments, aiming to significantly enhance success rates and reduce birth defects. The company closed a $4.5 million Series A funding round led by Firstime Ventures, with strategic participation from global pharmaceutical leader ROHTO. This latest investment brings the company’s total funding to $6.5 million, following a successful $2 million Seed round from private investors, including fertility clinic owners in Israel and abroad.
BAIBY’s is not the only one in Israel Startup Nation working in the field of fertility treatments. In February, Israeli scientists have made a breakthrough in treating infertility, this time in men. Researchers from the Technion in found a way, using sperm from mice, to treat male infertility. The scientists conducted a study they say reveals a potential new method to test the capacity of sperm to induce cell fusion, which could be used to diagnose male fertility issues.
Founded in 2020 by Dr. Nino Guy Cassuto, a Jewish-French doctor specializing in male fertility, and Gal Golov, an engineer expert in electro-optics who personally experienced the multifaceted difficulties inherent in repeated failed fertility treatments, BAIBYS’ autonomous sperm selection solution for In-Vitro Fertilization (IVF) is designed to analyze living sperm cells in real-time using machine vision (MV) and artificial intelligence (AI).
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
BAIBYS’ technology evaluates the sperm cells according to morphological criteria, which can only be identified using high magnification. The system recognizes structures in motion, to evaluate the quality of living sperm cells according to previously established criteria using proprietary AI algorithms. Utilizing robotics, BAIBYS’ system then autonomously selects and collects the sperm with the highest fertilization potential, ready to microinject into the egg in IVF procedures.
By leveraging ROHTO’s extensive global distribution network, the partnership aims to accelerate the market growth of BAIBYS innovative fertility devices said the companies. Additionally, ROHTO has secured the exclusive right to negotiate the distribution of BAIBYS solutions in the Asia Pacific region.
This collaboration will enable both companies to combine their expertise. ROHTO will diversify its business while capitalizing on BAIBYS™’ advanced technology to strengthen its presence in the fertility clinic market. The companies plan to explore joint research and development opportunities to leverage their respective proprietary technologies.
“The new partnership, which is not only financial, with a significant corporation like RHOTO opens up enormous possibilities for us in terms of marketing, R&D, and other areas,” said Dr. Yaron Silberman, CEO of BAIBYS. “We will make every effort to leverage this partnership to bring innovative products to market for the benefit of the many couples (1 in 6) suffering from infertility. In the coming months, we will pass significant milestones, with the crowning achievement being the start of sales in Europe later this year, assisted by our seed round investors and their network. We are proud to show the world that an innovative Israeli technology can help couples around the world to have healthy babies, during this challenging period.”
